Bristol Myers Squibb (CELG-RI) Total Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Total Non-Current Liabilities data on file, last reported at $61.5 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $61.5 billion, down 12.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.5 billion (down 12.74% YoY), and the FY2025 annual result was $66.5 billion, down 7.33% from the prior year.
• Total Non-Current Liabilities eased to $61.5 billion in Q1 2026 per CELG-RI's latest filing, from $66.5 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $75.8 billion in Q1 2024 and troughed at $55.6 billion in Q2 2023.
• A 5-year average of $65.0 billion and a median of $64.1 billion in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities dropped 13.03% in 2023, then soared 35.92% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $59.1 billion in 2022, then increased by 0.24% to $59.3 billion in 2023, then advanced by 21.08% to $71.7 billion in 2024, then dropped by 7.33% to $66.5 billion in 2025, then decreased by 7.47% to $61.5 billion in 2026.
• Business Quant data shows CELG-RI's Total Non-Current Liabilities at $61.5 billion in Q1 2026, $66.5 billion in Q4 2025, and $72.8 billion in Q3 2025.